GSK’s Zejula-Jemperli Combination Achieves Primary Endpoint in Ovarian Cancer Trial, Falls Short on Overall Survival
Trial Success:
GSK's Phase 3 FIRST trial, combining Jemperli with chemotherapy and Zejula maintenance, met its primary endpoint of progression-free survival (PFS) in patients with first-line advanced ovarian cancer124.
Overall Survival Miss:
Despite achieving the primary endpoint, the combination therapy missed the secondary endpoint of overall survival1.
Market Context:
Zejula and Lynparza are both approved for ovarian cancer maintenance in patients responding to first-line platinum chemotherapy, indicating a competitive landscape3.
Clinical Significance:
The combination of Jemperli and Zejula demonstrates potential in extending PFS in ovarian cancer patients, though further analysis is needed to understand the implications of missing the overall survival endpoint45.
Announcement:
GSK announced the topline results from the FIRST trial on December 20, 2024, highlighting the combination's efficacy in PFS but not in overall survival5.
Sources:
1. https://endpts.com/gsks-zejula-jemperli-combo-in-ovarian-cancer-hits-primary-endpoint-misses-on-overall-survival/
2. https://firstwordpharma.com/story/5922977
3. https://www.oncologypipeline.com/apexonco/jemperli-aims-ovarian-white-space
4. https://www.morningstar.com/news/dow-jones/202412201027/gsks-combination-of-cancer-drugs-shows-positive-results-in-late-stage-trial
5. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-trial-met-its-primary-endpoint-of-progression-free-survival-in-first-line-advanced-ovarian-cancer/